Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Primary Open Angle Glaucoma; Ocular Hypertension
Intervention: brinzolamide 1.0% (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Alcon Research Official(s) and/or principal investigator(s): John Liu, PhD, Principal Investigator, Affiliation: University of California, San Diego
Summary
This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1. 0%
compared to timolol 0. 5% when added to a prostaglandin analogue (PGA) as adjunctive therapy
over a 24 hour period in patients with glaucoma or ocular hypertension.
Clinical Details
Official title: A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: IOP-lowering at 8 and 16 weeks
Secondary outcome: Safety throughout the 16 weeks of the study
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Primary open angle glaucoma or ocular hypertension patients
Exclusion Criteria:
- Women of childbearing potential
- History of bronchial asthma, or severe chronic obstructive pulmonary disease
- Presence of acute glaucoma
Locations and Contacts
San Diego, California, United States
Additional Information
Starting date: September 2006
Last updated: April 7, 2012
|